search
Back to results

Moderate Intensity Aerobic Training in Sub-acute and Chronic Stroke Patients - the Influence on Brain Derived Neurotrophic Factor (BDNF) and Upper-limb Rehabilitation. A Protocol for a Randomized Control Trial and Health Economic Evaluation

Primary Purpose

Stroke

Status
Completed
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
Aerobic Training & UL Motor Training
Non-aerobic training & UL Motor Training
Sponsored by
Clare Maguire
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Stroke

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Hemiplegic stroke ischemic or intracerebral hemorrhagic > 3 months post- stroke
  • Active shoulder abduction, wrist and finger extension 10 degrees from a flexed position

Exclusion Criteria:

  • Contraindications to maximal exercise testing according to the American College of Sports Medicine guidelines
  • Severe perceptual problems
  • Concurrent neurological diagnoses e.g. Parkinsons disease
  • Comorbidities which may interfere with exercise participation
  • Significant cognitive impairment < 24 on the Montreal Cognitive Assessment Scale

Sites / Locations

  • RehaB clinic for Neurorehabilitation and Paraplegiology

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Aerobic Training & UL Motor Training

Non-aerobic Training & UL Motor Training

Arm Description

Aerobic training at 40%-59% Heart Rate Reserve (AT) increasing from personal maximum time (if < 40 mins) to 40 minutes followed by UL motor training with the Armeo®Spring/Senso/Pablo X2® 3 * weekly, 12 weeks

40 minutes non-aerobic gait & balance circuit training followed by UL motor training with the Armeo®Spring/Senso/Pablo X2® 3 * weekly, 12 weeks

Outcomes

Primary Outcome Measures

BDNF
Acute (immediate post exercise) and chronic (post-intervention) serum BDNF levels
Action Research Arm Test (ARAT)
A 19-Item standardised assessment of UL function measuring ADLs, coordination & dexterity.

Secondary Outcome Measures

The Fugl-Meyer Assessment - Upper Extremity Scale (FMA).
Instrument for measuring upper limb impairment after stroke. The Fugl-Meyer Assessment - Upper Extremity Scale (FMA). This is reliable, responsive and valid instrument for measuring upper limb impairment after stroke. Items are scored on a three-point ordinal scale: 0=cannot perform, 1=performs partially, 2=performs fully. Maximal Score 66.
10 meter walking test
A measurement of gait speed
Trunk Sway in standing with eyes closed
Standing balance
The Montreal Cognitive Assessment (MoCA©).
This is a rapid screen of cognitive performance to detect mild cognitive dysfunction. The test consists of 16 items and 11 categories to assess multiple cognitive domains. The maximal score is 30.
Corsi Block Test
Evaluates visuospatial short-term working memory
The Fatigue Severity Scale (FSS)
Measures post-stroke-fatigue. This is a 9-item, 7 point linkert scale scale which measures the effect of fatigue on activities and lifestyle. The higher the score the worse the fatigue.
Stroke Impact Scale
A disease specific Quality of Life measure.This is a 59 item measure in which 8 domains are assessed. Each item is a 5-point Linkert scale related to difficulty completing the scale . Summative scores are generated for each domain. A higher score indicates a better Performance.

Full Information

First Posted
October 7, 2018
Last Updated
December 28, 2022
Sponsor
Clare Maguire
Collaborators
Bildungszetrum Gesundheit Basel-Stadt, Rehab Basel
search

1. Study Identification

Unique Protocol Identification Number
NCT03701035
Brief Title
Moderate Intensity Aerobic Training in Sub-acute and Chronic Stroke Patients - the Influence on Brain Derived Neurotrophic Factor (BDNF) and Upper-limb Rehabilitation. A Protocol for a Randomized Control Trial and Health Economic Evaluation
Official Title
Does Moderate Intensity Aerobic Training Influence Serum Levels of BDNF in Sub-acute and Chronic Stroke Patients and Consequently Increase the Efficacy of Upper-limb Rehabilitation? A Study Protocol for a Randomized Control Trial With an Embedded Health Economic Evaluation.
Study Type
Interventional

2. Study Status

Record Verification Date
December 2022
Overall Recruitment Status
Completed
Study Start Date
October 8, 2018 (Actual)
Primary Completion Date
September 1, 2020 (Actual)
Study Completion Date
September 1, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Clare Maguire
Collaborators
Bildungszetrum Gesundheit Basel-Stadt, Rehab Basel

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The aim of this study is to evaluate the influence on three different training modalities on the blood concentration levels of a growth factor called Brain Derived Neurotrophic Factor (BDNF) and on the recovery of arm function following in sub-acute and chronic stroke survivors. The training modalities are 1. moderate intensity aerobic training on a bike ergonometer followed by robotic or sensor-based upper-limb training, 2. non-aerobic circuit training followed by robotic or sensor-based upper-limb training 3. circuit training alone.
Detailed Description
Background and Rationale:Brain-derived neurotrophic factor (BDNF) belongs to a group of neurotrophins which influence neuroplasticity by increasing long-term potentiation and axonal and dendritic growth. Levels of serum BDNF are increased following moderate intensity aerobic exercise (MAE) in animal and healthy subjects. The influence of MAE on BDNF following stroke and the resultant efficacy of motor training in this environment remains unclear. Objective(s):To investigate the influence of MAE on acute and chronic levels of serum BDNF in sub-acute and chronic stroke patients, the efficacy of robotic upper limb or sensor based motor task training in this environment and consequent effect on functional arm recovery compared to the same upper limb training following non-aerobic training circuit training, or non-aerobic circuit training alone To evaluate the cost-effectiveness of the interventions. Study Interventions: Group 1: moderate intensity AE 40 minutes, 3 times weekly followed after 20 minutes break by 40 minutes robotic or sensor-based upper-limb Training. Group2: non-aerobic gait and balance circuit training 40 mins 3 times weekly followed after 20 minutes break by 40 minutes robotic or sensor-based upper-limb training, group 3: 40 minutes non-aerobic gait and balance circuit training.In total 45 participants will be enrolled - 15 in each group.Study Duration:3 monthly Intervention period per intervention group, with a 3 month and 6 month follow-up. .

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Stroke

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
17 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Aerobic Training & UL Motor Training
Arm Type
Experimental
Arm Description
Aerobic training at 40%-59% Heart Rate Reserve (AT) increasing from personal maximum time (if < 40 mins) to 40 minutes followed by UL motor training with the Armeo®Spring/Senso/Pablo X2® 3 * weekly, 12 weeks
Arm Title
Non-aerobic Training & UL Motor Training
Arm Type
Active Comparator
Arm Description
40 minutes non-aerobic gait & balance circuit training followed by UL motor training with the Armeo®Spring/Senso/Pablo X2® 3 * weekly, 12 weeks
Intervention Type
Behavioral
Intervention Name(s)
Aerobic Training & UL Motor Training
Intervention Description
Aerobic training at 40%-59% Heart Rate Reserve (AT) increasing from personal maximum time (if < 40 mins) to 40 minutes followed by UL motor training with the Armeo®Spring/Senso/Pablo X2®
Intervention Type
Behavioral
Intervention Name(s)
Non-aerobic training & UL Motor Training
Intervention Description
40 minutes non-aerobic gait & balance circuit training followed by UL motor training with the Armeo®Spring/Senso/Pablo X2®
Primary Outcome Measure Information:
Title
BDNF
Description
Acute (immediate post exercise) and chronic (post-intervention) serum BDNF levels
Time Frame
12 weeks
Title
Action Research Arm Test (ARAT)
Description
A 19-Item standardised assessment of UL function measuring ADLs, coordination & dexterity.
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
The Fugl-Meyer Assessment - Upper Extremity Scale (FMA).
Description
Instrument for measuring upper limb impairment after stroke. The Fugl-Meyer Assessment - Upper Extremity Scale (FMA). This is reliable, responsive and valid instrument for measuring upper limb impairment after stroke. Items are scored on a three-point ordinal scale: 0=cannot perform, 1=performs partially, 2=performs fully. Maximal Score 66.
Time Frame
12 weeks
Title
10 meter walking test
Description
A measurement of gait speed
Time Frame
12 weeks
Title
Trunk Sway in standing with eyes closed
Description
Standing balance
Time Frame
12 weeks
Title
The Montreal Cognitive Assessment (MoCA©).
Description
This is a rapid screen of cognitive performance to detect mild cognitive dysfunction. The test consists of 16 items and 11 categories to assess multiple cognitive domains. The maximal score is 30.
Time Frame
12 weeks
Title
Corsi Block Test
Description
Evaluates visuospatial short-term working memory
Time Frame
12 weeks
Title
The Fatigue Severity Scale (FSS)
Description
Measures post-stroke-fatigue. This is a 9-item, 7 point linkert scale scale which measures the effect of fatigue on activities and lifestyle. The higher the score the worse the fatigue.
Time Frame
12 weeks
Title
Stroke Impact Scale
Description
A disease specific Quality of Life measure.This is a 59 item measure in which 8 domains are assessed. Each item is a 5-point Linkert scale related to difficulty completing the scale . Summative scores are generated for each domain. A higher score indicates a better Performance.
Time Frame
12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Hemiplegic stroke ischemic or intracerebral hemorrhagic > 3 months post- stroke Active shoulder abduction, wrist and finger extension 10 degrees from a flexed position Exclusion Criteria: Contraindications to maximal exercise testing according to the American College of Sports Medicine guidelines Severe perceptual problems Concurrent neurological diagnoses e.g. Parkinsons disease Comorbidities which may interfere with exercise participation Significant cognitive impairment < 24 on the Montreal Cognitive Assessment Scale
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clare Maguire, PhD
Organizational Affiliation
Bern University of Applied Sciences
Official's Role
Principal Investigator
Facility Information:
Facility Name
RehaB clinic for Neurorehabilitation and Paraplegiology
City
Basel
ZIP/Postal Code
4055
Country
Switzerland

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Moderate Intensity Aerobic Training in Sub-acute and Chronic Stroke Patients - the Influence on Brain Derived Neurotrophic Factor (BDNF) and Upper-limb Rehabilitation. A Protocol for a Randomized Control Trial and Health Economic Evaluation

We'll reach out to this number within 24 hrs